ClinicalTrials.gg
Active, not recruitingNCT04822181ESSENCEUpdated Oct 13, 2026

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

A Phase 3 interventional study of Semaglutide and Placebo in Non-alcoholic Steatohepatitis, sponsored by Novo Nordisk A/S. Active, not recruiting at 558 sites in 39 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,205
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing semaglutide in Non-alcoholic Fatty Liver Disease — 4 open to participants now, 8 under way, 1 of them phase 3. Semaglutide · Non-alcoholic Fatty Liver Disease.

Enrollment
Largest of 16
1,205 · median 88
Started
2021
with 3 others
Phase 3
Only one
of the 16
Registered
8th of 16
by date
Lead sponsor
4 of 16
Novo Nordisk A/S

Among the 16 studies testing semaglutide in Non-alcoholic Fatty Liver Disease, this one has the largest enrollment, is one of 4 that started in 2021, is the only one in phase 3, and was the 8th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 323 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

4 of the 16 studies testing semaglutide in Non-alcoholic Fatty Liver Disease are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 220 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 125 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing semaglutide in Non-alcoholic Fatty Liver Disease, or all of them as a file.
02

Study summary

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries.

Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance.

Participants will need to inject themselves with medicine under the skin. Participants will need to do this once a week.

The study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day.

Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.

03

Conditions studied

  • Non-alcoholic Steatohepatitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age above or equal to 18 years at the time of signing .
  • Histological evidence of NASH based on a central pathologist evaluation of the baseline liver . The baseline liver biopsy can be a historical biopsy obtained within 180 days prior to the screening visit (V1).
  • Histological evidence of fibrosis stage 2 or stage 3 according to the NASH CRN (Clinical Research Network) classification based on a central pathologist evaluation of the baseline liver biopsy.
  • A histological NAS (Non-alcoholic fatty liver disease Activity Score) above or equal to 4 with a score of 1 or more in steatosis, lobular inflammation and hepatocyte ballooning based on a central pathologist evaluation of the baseline liver biopsy.

Exclusion criteria

Exclusion Criteria:

  • Documented causes of chronic liver disease other than non-alcoholic fatty liver disease (NAFLD)
  • Positive , positive anti-, positive at screening (V2A) or any known presence of HCV RNA or HBsAg within 2 years of screening (V2A).
  • Presence or history of ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis or liver transplantation at randomisation.
  • Known or suspected excessive consumption of alcohol (greater than 20 g/day for women or greater than 30 g/day for men) or alcohol dependence (assessed by the Alcohol Use Disorders Identification Test (AUDIT questionnaire)).
  • Treatment with vitamin E (at doses greater than or equal to 800 IU/day) or pioglitazone or medications approved for treatment of NASH which has not been at a stable dose in the period from 90 days prior to the screening visit (V2A). In addition, for subjects with historical liver taken more than 90 days prior to screening, treatment should be at a stable dose from time of biopsy until screening.
  • Treatment with GLP-1 RAs in the period from 90 days prior to the screening visit (V2A). In addition, for subjects with historical liver biopsies taken more than 90 days prior to screening, any treatment with GLP-1 RAs from time of biopsy until screening (V2A).
  • Treatment with glucose-lowering agent(s) (other than GLP-1 RAs), lipid-lowering medication or weight loss medication not stable in the opinion of the investigator in the period from 90 days prior to the screening visit (V2A). In addition, for subjects with historical liver biopsies taken more than 90 days prior to screening, treatment should be at a stable dose in the opinion of the investigator from time of biopsy until screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,205 participants (actual)

Study arms

  • Experimental
    Semaglutide OW (once weekly )

    Semaglutide administrated subcutaneously once weekly

    Drug: Semaglutide

  • Placebo comparator
    Placebo

    Placebo administrated subcutaneously once weekly

    Drug: Placebo

Interventions

  • Semaglutide administrated subcutaneously (under the skin) once weekly there will be a period of dose escalation before reaching the target dose.

  • DrugPlacebo

    Placebo administrated subcutaneously (under the skin) once weekly.

06

What researchers measure

Primary outcomes

  1. Part 1: Resolution of steatohepatitis and no worsening of liver fibrosis (Yes/No)

    Count of subject

    Time frame: From randomisation (week 0) to week 72

  2. Part 1: Improvement in liver fibrosis and no worsening of steatohepatitis (Yes/No)

    Count of subject

    Time frame: From randomisation (week 0) to week 72

  3. Part 2: Cirrhosis-free survival (Yes/No)

    Count of subject

    Time frame: From randomisation (week 0) to week 240

Secondary outcomes

  1. Change in body weight

    Percentage

    Time frame: From randomisation (week 0) to week 72

  2. Resolution of steatohepatitis and improvement in liver fibrosis (Yes/No)

    Count of subject

    Time frame: From randomisation (week 0) to week 72

  3. Change in SF-36 (Short Form 36) Bodily Pain

    Score points

    Time frame: From randomisation (week 0) to week 72

  4. Change in body weight

    Percentage

    Time frame: From randomisation (week 0) to week 240

  5. Improvement in steatohepatitis with at least a 2-point reduction in NAS and no worsening of fibrosis (Yes/No)

    Count of subject

    Time frame: From randomisation (week 0) to week 72

  6. Change in histology-assessed liver collagen proportionate area

    Ratio to baseline

    Time frame: From randomisation (week 0) to week 72

  7. Worsening in steatohepatitis (Yes/No)

    Count of subject

    Time frame: From randomisation (week 0) to week 72

  8. Improvement in histology-assessed ballooning (Yes/No)

    Count of subject

    Time frame: From randomisation (week 0) to week 72

  9. Improvement in histology-assessed inflammation (Yes/No)

    Count of subject

    Time frame: From randomisation (week 0) to week 72

  10. Improvement in histology-assessed steatosis (Yes/No)

    Count of subject

    Time frame: From randomisation (week 0) to week 72

  11. NASH resolution (ballooning of 0, inflammation of 0-1) and above or equal to 2point NAS reduction with no worsening of fibrosis

    Count of subject

    Time frame: From randomisation (week 0) to week 72

  12. Progression of liver fibrosis in patients with F2 at baseline (Yes/No)

    Count of subject

    Time frame: From randomisation (week 0) to week 72

  13. Progression of liver fibrosis

    Count of subject

    Time frame: From randomisation (week 0) to week 72

  14. Resolution of steatohepatitis and no worsening of liver fibrosis (Yes/No)

    Count of subject

    Time frame: From randomisation (week 0) to week 240

  15. Improvement in liver fibrosis and no worsening of steatohepatitis (Yes/No)

    Count of subject

    Time frame: From randomisation (week 0) to week 240

  16. Absence of histological evidence of NASH (Yes/No)

    Count of subject

    Time frame: From randomisation (week 0) to week 240

  17. Changes in liver stiffness values assessed by transient elastography (FibroScan®)

    Ratio to baseline

    Time frame: From randomisation (week 0) to week 72 and week 240

  18. Change in ELF (Enhanced Liver Fibrosis) score

    Logarithm

    Time frame: From randomisation (week 0) to week 72 and week 240

  19. Change in ALT (alanine aminotransferase)

    Ratio to baseline

    Time frame: From randomisation (week 0) to week 72 and week 240

  20. Change in AST (aspartate aminotransferase)

    Ratio to baseline

    Time frame: From randomisation (week 0) to week 72 and week 240

  21. Change in CAP (Controlled Attenuation Parameter) values assessed by transient elastography (FibroScan)

    Absolute change

    Time frame: From randomisation (week 0) to week 72 and week 240

  22. Change in FAST (FibroScan-AST) score

    Probability (absolute change)

    Time frame: From randomisation (week 0) to week 72 and week 240

  23. Change in Pro-C3 (pro-peptide of type III collagen)

    Logarithm

    Time frame: From randomisation (week 0) to week 72 and week 240

  24. Change in inflammation assessed by hsCRP (High Sensitive C-Reactive Protein)

    Ratio to baseline

    Time frame: From randomisation (week 0) to week 72 and week 240

  25. Change in HbA1c (glycated haemoglobin)

    Percentage-points (absolute change)

    Time frame: From randomisation (week 0) to week 72 and week 240

  26. Change in triglyceride

    Ratio to baseline

    Time frame: From randomisation (week 0) to week 72 and week 240

  27. Change in free fatty acids

    Ratio to baseline

    Time frame: From randomisation (week 0) to week 72 and week 240

  28. Change in LDL (low-density lipoprotein) cholesterol

    Ratio to baseline

    Time frame: From randomisation (week 0) to week 72 and week 240

  29. Change in HDL (High density lipoprotein ) cholesterol

    Ratio to baseline

    Time frame: From randomisation (week 0) to week 72 and week 240

  30. Time to first MACE(Major Adverse Cardiovascular event ) (composite endpoint)

    Days

    Time frame: From randomisation (week 0) to week 240

  31. Major cardio-hepatic event-free survival (Yes/No)

    Count of subject

    Time frame: From randomisation (week 0) to week 240

  32. Changes in SF-36 (Short Form 36 v2.0 acute ) Physical Component Summary

    Score points

    Time frame: From randomisation (week 0) to week 72 and week 240

  33. Changes in SF-36 Mental Component Summary

    Score points

    Time frame: From randomisation (week 0) to week 72 and week 240

  34. Change in SF-36 Bodily Pain

    Score points

    Time frame: From randomisation (week 0) to week 240

  35. Changes in NASH-CHECK Abdominal Pain

    Score points

    Time frame: From randomisation (week 0) to week 72 and week 240

07

Study locations

558 sites

Showing the first 100 of 558 sites across 39 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Newsome PN, Sanyal AJ, Engebretsen KA, Kliers I, Ostergaard L, Vanni D, Bugianesi E, Rinella ME, Roden M, Ratziu V. Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Aliment Pharmacol Ther. 2024 Dec;60(11-12):1525-1533. doi: 10.1111/apt.18331. Epub 2024 Oct 16. PubMed 39412509 ↗
  • Nakajima A, Okanoue T, Hiasa Y, Takahashi H, Opuni K, Kosaka N, Nishida T, Sanyal AJ. Semaglutide in Japanese participants with metabolic dysfunction-associated steatohepatitis: a subgroup analysis of the ESSENCE trial. J Gastroenterol. 2026 Aug 28. doi: 10.1007/s00535-026-02507-0. Online ahead of print. PubMed 42663669 ↗
  • Sanyal AJ, Newsome PN, Kliers I, Ostergaard LH, Long MT, Kjaer MS, Cali AMG, Bugianesi E, Rinella ME, Roden M, Ratziu V; ESSENCE Study Group. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025 Jun 5;392(21):2089-2099. doi: 10.1056/NEJMoa2413258. Epub 2025 Apr 30. PubMed 40305708 ↗
  • Jensen EL, Israelsen M, Krag A. Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists. Hepatol Commun. 2024 Oct 10;8(11):e0561. doi: 10.1097/HC9.0000000000000561. eCollection 2024 Nov 1. PubMed 39392766 ↗
  • Rowe IA, Allen AM. Hepatic steatosis provides the terroir that promotes the development of cardiovascular risk factors and disease. Hepatology. 2023 Jun 1;77(6):1843-1845. doi: 10.1097/HEP.0000000000000327. Epub 2023 Feb 6. No abstract available. PubMed 36738088 ↗

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Apr 2029, 96 months after the start.

Of 34 phase 3 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 61. This study's planned 96 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2021
First posted
Mar 30, 2021
StartActual
Apr 1, 2021
Primary completionEst.
Apr 25, 2029
CompletionEst.
Apr 25, 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04822181
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 30, 2021
Start date
Apr 1, 2021
Primary completion
Apr 25, 2029 (estimated)
Completion
Apr 25, 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion